CN111150756A - Composition for treating prostatitis and preparation method thereof - Google Patents
Composition for treating prostatitis and preparation method thereof Download PDFInfo
- Publication number
- CN111150756A CN111150756A CN202010032459.5A CN202010032459A CN111150756A CN 111150756 A CN111150756 A CN 111150756A CN 202010032459 A CN202010032459 A CN 202010032459A CN 111150756 A CN111150756 A CN 111150756A
- Authority
- CN
- China
- Prior art keywords
- composition
- seed oil
- parts
- preparation
- cannabidiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 56
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 56
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 56
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 56
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 56
- 239000008171 pumpkin seed oil Substances 0.000 claims abstract description 20
- 239000010460 hemp oil Substances 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000499 gel Substances 0.000 claims description 56
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
- 108010010803 Gelatin Proteins 0.000 claims description 44
- 239000008273 gelatin Substances 0.000 claims description 44
- 229920000159 gelatin Polymers 0.000 claims description 44
- 235000019322 gelatine Nutrition 0.000 claims description 44
- 235000011852 gelatine desserts Nutrition 0.000 claims description 44
- 235000009508 confectionery Nutrition 0.000 claims description 42
- 239000003292 glue Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 21
- 239000008213 purified water Substances 0.000 claims description 20
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
- 239000005715 Fructose Substances 0.000 claims description 15
- 229930091371 Fructose Natural products 0.000 claims description 15
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 15
- 239000007901 soft capsule Substances 0.000 claims description 15
- 239000000600 sorbitol Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 238000007599 discharging Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 241000218236 Cannabis Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- 239000002356 single layer Substances 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 229920001938 Vegetable gum Polymers 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 8
- 239000005642 Oleic acid Substances 0.000 abstract description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 208000019901 Anxiety disease Diseases 0.000 abstract description 4
- 230000036506 anxiety Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 2
- 235000020778 linoleic acid Nutrition 0.000 abstract description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 description 25
- 229940098330 gamma linoleic acid Drugs 0.000 description 15
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 15
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 15
- 238000011068 loading method Methods 0.000 description 15
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 230000027939 micturition Effects 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 7
- 235000021313 oleic acid Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 5
- 238000010981 drying operation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229960002969 oleic acid Drugs 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000000832 Ayote Nutrition 0.000 description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 2
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 2
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000408747 Lepomis gibbosus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001904 cucurbitacins Chemical class 0.000 description 2
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000015136 pumpkin Nutrition 0.000 description 2
- 235000020236 pumpkin seed Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009844 Cucumis melo var conomon Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 206010062903 Urethritis noninfective Diseases 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for treating prostatitis and a preparation method thereof, wherein the effective components of the composition comprise hemp seed oil, pumpkin seed oil and Cannabidiol (CBD), and the weight percentage of the effective components in the composition is 20-100%; based on the weight of the effective components, the hemp seed oil accounts for 30-45 wt%, the pumpkin seed oil accounts for 20-50 wt%, and the Cannabidiol (CBD) accounts for 10-40 wt%. The invention adopts the medicinal and edible components of the hemp seed oil, the pumpkin seed oil and the Cannabidiol (CBD) to be matched for use, and the Cannabidiol (CBD) supplements unsaturated fatty acids such as oleic acid and linoleic acid for patients on the basis of relieving anxiety of the patients and regulating the immunity of the patients, can effectively prevent and improve the symptoms of prostatitis, and can be applied to the preparation of health-care foods, special medical foods and medicines for treating the prostatitis.
Description
Technical Field
The invention belongs to the technical field of health-care food, and particularly relates to a composition for treating prostatitis and a preparation method thereof.
Background
The prostate is the largest parenchymal organ in the male accessory glands and prostate health is of considerable importance to men. The prostatitis causes complex and various, mainly shows urethral irritation symptoms and chronic pelvic pain, seriously affects the life quality of patients and causes serious harm to the body health of the patients. Clinically, the prostatitis is divided into 4 types, namely type I, type II, type III and type IV prostatitis, and the prostatitis of different types has different causes but can also be the result of accumulation of multiple causes. Prostatitis can be caused by frequent staying up all night, lack of exercise for a long time, long-term compensation, no regular life and the like, so that the prostatitis symptoms are continuously aggravated. The onset of prostatitis is a trend of younger onset due to lack of popularization and cognition of the symptoms of prostatitis.
The traditional treatment mode is mainly based on the treatment of a Chinese and western medicine combined prescription, and common medicines such as antibiotics, anti-inflammatory drugs, α receptor blockers, plant medicines, immunosuppressants and the like need to be taken according to the treatment course, but the long-time administration of the antibiotics can affect the physical health.
Fructus cannabis is a dry mature seed of cannabis sativa of the family Moraceae, is sweet and neutral in nature, and is a typical homologous plant of medicine and food. The hemp seed oil contains rich vegetable oil, mainly contains monounsaturated fatty acid and polyunsaturated fatty acid, such as oleic acid, linoleic acid, alpha-linolenic acid, gamma-linoleic acid and other essential unsaturated fatty acids. Among them, gamma-linoleic acid (GLA) is a polyunsaturated fatty acid having various special physiological functions necessary for the human body, and plays an important role in metabolism and physiological regulation in the body. After entering cell walls, gamma-linoleic acid (GLA) binds to or inserts into cell membranes, and changes the fluidity and other physiological properties of the membranes, thereby inhibiting the growth of the thalli. Thus, gamma-linoleic acid (GLA) is considered a nutrient for a particular health care effect.
Pumpkin seeds, also known as "sweet melon" or "rice melon", are seeds of pumpkin belonging to the genus Cucurbita of the family Cucurbitaceae. The pumpkin seed oil contains unsaturated fatty acids such as oleic acid, linoleic acid, linolenic acid, palmitic acid, stearic acid, arachidic acid, vaccenic acid, erucic acid, etc., wherein the total content of the unsaturated fatty acids accounts for 74.9% of the total content of the fatty acids, and the content of the oleic acid and the linoleic acid accounts for 35% -50% of the dry weight of the pumpkin seeds; furthermore, the unsaturated fatty acids in the pumpkin seed oil mainly contain polyunsaturated fatty acids (PUFAs). The pumpkin seed oil also contains abundant vitamins such as fat-soluble vitamin E, and a certain amount of phylloquinone-vitamin E. The pumpkin seed oil is rich in mineral substances, and zinc, magnesium, iron, selenium and the like have special biological effects. In addition, pumpkin seed oil also contains pumpkin essence which is an active biological activator called male hormone, has the efficacy of human body hormone, can eliminate the initial swelling of prostate, and can effectively prevent and treat urinary system diseases and prostatic hyperplasia.
Cannabidiol (CBD) is a pure natural component extracted from industrial cannabis sativa plants in yunnan, has good tolerance, and has certain therapeutic properties against a variety of diseases such as anxiety, neurological diseases, epilepsy, tumors, inflammation, liver injury, diabetes, pain, and the like. Cannabidiol (CBD) may play a metabolic and immunomodulatory role by regulating inflammatory factor levels, controlling interferon production, and the like. The receptors associated with the anxiolytic effect of Cannabidiol (CBD) are: the CB1 receptor, the TRPV1 receptor and the 5-HT1A receptor. Cannabidiol (CBD) has a low affinity for the CB1 receptor, but it acts as an indirect agonist. Cannabidiol (CBD) acts as a TRPV1 agonist at high concentrations, possibly acting by interfering with the inactivation of anandamide. The 5-HT1A receptor is currently identified as an anxiolytic target, and Cannabidiol (CBD) exerts anxiolytic effects by agonizing the 5-HT1A receptor.
The composition adopts medicinal and edible components, is healthy and safe, is beneficial to improving the symptoms of prostatitis, and can be used as a composition for improving the symptoms of prostatitis.
Disclosure of Invention
One aspect of the present invention is to provide a composition for treating prostatitis.
In order to achieve the purpose, the invention adopts the following technical scheme:
a composition for treating prostatitis comprises effective components including hemp seed oil, pumpkin seed oil and Cannabidiol (CBD), wherein the effective components account for 20-100% of the weight of the composition.
In some embodiments of the present invention, the hemp seed oil is 30-45 wt%, the pumpkin seed oil is 20-50 wt%, and the Cannabidiol (CBD) is 10-40 wt%, based on the weight of the active ingredient.
In some embodiments of the invention, the composition is an oral formulation; the preparation is in the form of electuary, distillate, soft capsule, oral liquid, fresh juice, hard capsule, granule, tablet, powder, tea beverage or medicated liquor.
In further embodiments, the formulation is a soft gelatin capsule of the vegetable gelatin type, animal gelatin type, precipitated gelatin type. The existing products mostly make health-care food into soft capsule dosage forms, and the content of the soft capsule contains polyunsaturated fatty acid liquid, so that the phenomenon of leakage is easy to occur in conventional storage, and the eating is influenced.
In a further embodiment, the composition further comprises an auxiliary material, and the auxiliary material comprises the following components in parts by weight: 5-30 parts of glycerol, 5-50 parts of gelatin, 0.2-5 parts of fructose, 0.2-5 parts of sorbitol and 5-50 parts of purified water. Preferably, the auxiliary materials comprise the following components in parts by weight: 5-20 parts of glycerol, 5-40 parts of gelatin, 0.2-4 parts of fructose, 0.2-3 parts of sorbitol and 5-60 parts of purified water.
It is a further object of the present invention to provide a method for preparing the above composition, comprising the steps of:
(1) preparing glue solution: putting glycerol and purified water into a device, stirring, adding gelatin, fructose and sorbitol when the temperature of the material liquid is raised to 70-75 ℃, vacuumizing, continuously heating to 80-85 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the glue solution at 70-75 ℃, vacuumizing again until the glue solution is free of bubbles and the viscosity reaches 20000-;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine;
(4) molding: performing the pressed gel candy by a rotating cage, drying until the rubber reaches the preset hardness, and removing unqualified products to obtain the composition for treating prostatitis.
In a further embodiment, the discharging process in step (1) is carried out by filtering with a single-layer 100-mesh filter bag, and the pressurization is not more than 0.06 MPa; standing for 2-24 h.
In a further embodiment, the gel candy of step (3) has a gum thickness of 0.75 to 0.80 mm; during preparation, the rotation speed of the gel candy machine is 2.0-3.5rpm, the heat preservation temperature of the glue solution is 70 ℃, and the temperature of the spray body is 55 ℃.
In a further embodiment, the preset hardness in the step (4) is 60 degrees, and the rubber skin contains 3-8% of water.
The invention also provides the application of the composition in preparing health-care food, special medical food and medicines for preventing and treating prostatitis.
The invention has the beneficial effects that:
the edible and medicinal components of the hemp seed oil, pumpkin seed oil and Cannabidiol (CBD) are matched for use, the hemp seed oil is rich in oleic acid, linoleic acid, alpha-linolenic acid, gamma-linoleic acid (GLA) and other human essential unsaturated fatty acids, and after the gamma-linoleic acid (GLA) enters cell walls, the hemp seed oil can be combined with or inserted into cell membranes to change the fluidity and other physiological properties of the membranes, so that the growth of thalli can be effectively inhibited; the pumpkin seed oil is rich in unsaturated fatty acids such as oleic acid and linoleic acid, contains cucurbitacin, vitamins and mineral substances, supplements elements required by a human body, can eliminate initial swelling of prostate, has a good prevention and treatment effect on urinary system and prostatic hyperplasia, can effectively relieve anxiety, can play a role in metabolism and immunoregulation by regulating and controlling the level of inflammatory factors and controlling the generation of interferon, is healthy and safe, can be taken for a long time, and can effectively improve the symptoms of prostatitis.
Drawings
In order to more clearly illustrate the detailed description of the invention or the technical solutions in the prior art, the drawings that are needed in the detailed description of the invention or the prior art will be briefly described below. Throughout the drawings, like elements or portions are generally identified by like reference numerals. In the drawings, elements or portions are not necessarily drawn to scale.
Fig. 1 is a production process diagram of the treatment of prostatitis according to one embodiment of the invention.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to the accompanying drawings. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. In the quantitative tests in the following examples, three replicates were set, and the data are the mean or the mean ± standard deviation of the three replicates.
Example 1
The embodiment is a preparation method of the composition for treating prostatitis in the form of soft capsules, and the raw materials for preparing the composition for treating prostatitis in the form of soft capsules comprise the following components in parts by weight: 22.5 parts of hemp seed oil, 22.5 parts of pumpkin seed oil, 5 parts of Cannabidiol (CBD), 5.4 parts of glycerol, 12 parts of gelatin, 0.6 part of fructose, 0.6 part of sorbitol and 11.4 parts of purified water.
The preparation method comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a gelatin melting tank, stirring and circulating a hot water system, adding gelatin, fructose (dissolved by a small amount of purified water) and sorbitol when the temperature of the feed liquid is raised to 75 ℃, vacuumizing until the vacuum degree in the gelatin melting tank reaches-0.08 Mpa, continuously heating to 80 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the gelatin solution at 70 ℃, vacuumizing again until the gelatin solution is bubble-free and the viscosity reaches 20000-; filtering the glue solution by a single-layer 100-mesh filter bag in the discharging process, wherein the discharging pressure is not more than 0.06 MPa; storing the glue solution in a heat-preserving barrel, preserving heat at 70 ℃, and standing for 2-24 h;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine; the pelleting die adopts OB14#, the rotating speed is 2.0-3.5rpm, the thickness of the rubber is 0.75-0.80mm, the heat preservation temperature of the rubber solution is 70 ℃, the temperature of the spraying body is 55 ℃, the standard loading is 0.400 g/grain, and the loading range is as follows: 0.380-0.420 g/grain, the average loading is more than or equal to 0.400 g/grain, the grain weight (wet weight) range is as follows: 0.880-0.920 g/grain;
(4) molding: performing the pressed gel candy by four or eight sections of rotating cages, and then drying until the gel is dried until the gel hardness is 60 degrees (the moisture of the gel is 3-8%); the reference time for the drying operation was 24h, and the standard for pill collection: particle weight (dry weight) range: 0.67-0.73g per granule, and removing unqualified products to obtain the composition for treating prostatitis.
Example 2
The embodiment is a preparation method of the composition for treating prostatitis in the form of soft capsules, and the raw materials for preparing the composition for treating prostatitis in the form of soft capsules comprise the following components in parts by weight: 20 parts of hemp seed oil, 20 parts of pumpkin seed oil, 10 parts of Cannabidiol (CBD), 5 parts of glycerol, 13 parts of gelatin, 1 part of fructose, 1 part of sorbitol and 10 parts of purified water.
The preparation method comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a gelatin melting tank, stirring and circulating a hot water system, adding gelatin, fructose (dissolved by a small amount of purified water) and sorbitol when the temperature of the feed liquid is raised to 75 ℃, vacuumizing until the vacuum degree in the gelatin melting tank reaches-0.08 Mpa, continuously heating to 80 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the gelatin solution at 70 ℃, vacuumizing again until the gelatin solution is bubble-free and the viscosity reaches 20000-; filtering the glue solution by a single-layer 100-mesh filter bag in the discharging process, wherein the discharging pressure is not more than 0.06 MPa; storing the glue solution in a heat-preserving barrel, preserving heat at 70 ℃, and standing for 2-24 h;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine; the pelleting die adopts OB14#, the rotating speed is 2.0-3.5rpm, the thickness of the rubber is 0.75-0.80mm, the heat preservation temperature of the rubber solution is 70 ℃, the temperature of the spraying body is 55 ℃, the standard loading is 0.400 g/grain, and the loading range is as follows: 0.380-0.420 g/grain, the average loading is more than or equal to 0.400 g/grain, the grain weight (wet weight) range is as follows: 0.880-0.920 g/grain;
(4) molding: performing the pressed gel candy by four or eight sections of rotating cages, and then drying until the gel is dried until the gel hardness is 60 degrees (the moisture of the gel is 3-8%); the reference time for the drying operation was 24h, and the standard for pill collection: particle weight (dry weight) range: 0.67-0.73g per granule, and removing unqualified products to obtain the composition for treating prostatitis.
Example 3
The embodiment is a preparation method of the composition for treating prostatitis in the form of soft capsules, and the raw materials for preparing the composition for treating prostatitis in the form of soft capsules comprise the following components in parts by weight: 17.5 parts of hemp seed oil, 17.5 parts of pumpkin seed oil, 15 parts of Cannabidiol (CBD), 5 parts of glycerol, 14 parts of gelatin, 1.5 parts of fructose, 1 part of sorbitol and 8.5 parts of purified water.
The preparation method comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a gelatin melting tank, stirring and circulating a hot water system, adding gelatin, fructose (dissolved by a small amount of purified water) and sorbitol when the temperature of the feed liquid is raised to 75 ℃, vacuumizing until the vacuum degree in the gelatin melting tank reaches-0.08 Mpa, continuously heating to 80 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the gelatin solution at 70 ℃, vacuumizing again until the gelatin solution is bubble-free and the viscosity reaches 20000-; filtering the glue solution by a single-layer 100-mesh filter bag in the discharging process, wherein the discharging pressure is not more than 0.06 MPa; storing the glue solution in a heat-preserving barrel, preserving heat at 70 ℃, and standing for 2-24 h;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine; the pelleting die adopts OB14#, the rotating speed is 2.0-3.5rpm, the thickness of the rubber is 0.75-0.80mm, the heat preservation temperature of the rubber solution is 70 ℃, the temperature of the spraying body is 55 ℃, the standard loading is 0.400 g/grain, and the loading range is as follows: 0.380-0.420 g/grain, the average loading is more than or equal to 0.400 g/grain, the grain weight (wet weight) range is as follows: 0.880-0.920 g/grain;
(4) molding: performing the pressed gel candy by four or eight sections of rotating cages, and then drying until the gel is dried until the gel hardness is 60 degrees (the moisture of the gel is 3-8%); the reference time for the drying operation was 24h, and the standard for pill collection: particle weight (dry weight) range: 0.67-0.73g per granule, and removing unqualified products to obtain the composition for treating prostatitis.
Example 4
The embodiment is a preparation method of the composition for treating prostatitis in the form of soft capsules, and the raw materials for preparing the composition for treating prostatitis in the form of soft capsules comprise the following components in parts by weight: 15 parts of hemp seed oil, 15 parts of pumpkin seed oil, 20 parts of Cannabidiol (CBD), 5 parts of glycerol, 12 parts of gelatin, 1 part of fructose, 1 part of sorbitol and 11 parts of purified water.
The preparation method comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a gelatin melting tank, stirring and circulating a hot water system, adding gelatin, fructose (dissolved by a small amount of purified water) and sorbitol when the temperature of the feed liquid is raised to 75 ℃, vacuumizing until the vacuum degree in the gelatin melting tank reaches-0.08 Mpa, continuously heating to 80 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the gelatin solution at 70 ℃, vacuumizing again until the gelatin solution is bubble-free and the viscosity reaches 20000-; filtering the glue solution by a single-layer 100-mesh filter bag in the discharging process, wherein the discharging pressure is not more than 0.06 MPa; storing the glue solution in a heat-preserving barrel, preserving heat at 70 ℃, and standing for 2-24 h;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine; the pelleting die adopts OB14#, the rotating speed is 2.0-3.5rpm, the thickness of the rubber is 0.75-0.80mm, the heat preservation temperature of the rubber solution is 70 ℃, the temperature of the spraying body is 55 ℃, the standard loading is 0.400 g/grain, and the loading range is as follows: 0.380-0.420 g/grain, the average loading is more than or equal to 0.400 g/grain, the grain weight (wet weight) range is as follows: 0.880-0.920 g/grain;
(4) molding: performing the pressed gel candy by four or eight sections of rotating cages, and then drying until the gel is dried until the gel hardness is 60 degrees (the moisture of the gel is 3-8%); the reference time for the drying operation was 24h, and the standard for pill collection: particle weight (dry weight) range: 0.67-0.73g per granule, and removing unqualified products to obtain the composition for treating prostatitis.
Comparative example 1
The comparative example is the preparation of the composition for treating prostatitis in the form of soft capsules, and the raw materials for preparing the composition for treating prostatitis in the form of soft capsules comprise the following components in parts by weight: 15 parts of hemp seed oil, 20 parts of Cannabidiol (CBD), 20 parts of glycerol, 10 parts of gelatin, 5 parts of fructose, 5 parts of sorbitol and 10 parts of purified water.
The preparation method comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a gelatin melting tank, stirring and circulating a hot water system, adding gelatin, fructose (dissolved by a small amount of purified water) and sorbitol when the temperature of the feed liquid is raised to 75 ℃, vacuumizing until the vacuum degree in the gelatin melting tank reaches-0.08 Mpa, continuously heating to 80 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the gelatin solution at 70 ℃, vacuumizing again until the gelatin solution is bubble-free and the viscosity reaches 20000-; filtering the glue solution by a single-layer 100-mesh filter bag in the discharging process, wherein the discharging pressure is not more than 0.06 MPa; storing the glue solution in a heat-preserving barrel, preserving heat at 70 ℃, and standing for 2-24 h;
(2) preparation of gel candy content: mixing oleum Cannabis and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine; the pelleting die adopts OB14#, the rotating speed is 2.0-3.5rpm, the thickness of the rubber is 0.75-0.80mm, the heat preservation temperature of the rubber solution is 70 ℃, the temperature of the spraying body is 55 ℃, the standard loading is 0.400 g/grain, and the loading range is as follows: 0.380-0.420 g/grain, the average loading is more than or equal to 0.400 g/grain, the grain weight (wet weight) range is as follows: 0.880-0.920 g/grain;
molding: performing the pressed gel candy by four or eight sections of rotating cages, and then drying until the gel is dried until the gel hardness is 60 degrees (the moisture of the gel is 3-8%); the reference time for the drying operation was 24h, and the standard for pill collection: particle weight (dry weight) range: 0.67-0.73g per granule, and removing unqualified products to obtain the composition for treating prostatitis.
Performance effects
1. Prostatitis treating composition content determination experiment
The fatty acid content was determined according to the method for determining fatty acids in GB 5009.168-2016. The measurement results of the composition for treating prostatitis obtained in example 1 are shown in table 1.
TABLE 1 determination of fatty acid content of composition for treating prostatitis
2. Typical case of composition for treating prostatitis comprising the composition for treating prostatitis according to the present invention
Typical case 1
The patients: male, age 45
The diseased condition is: the hospital diagnoses prostatitis, frequent micturition, urgent micturition, odynuria and dysuria.
The implementation scheme is as follows: the fructus Cannabis oil gel candy is taken before meal, 3 times daily for the first 30 days, and 800mg x 4 granules are taken each time; the administration is continued for 30 days, 2 times daily, 800 mg/4 capsules each time.
The result of the scheme is as follows: intermittent frequent micturition, urgent micturition and odynuria are improved, and urination is not obviously uncomfortable.
Typical case 2
The patients: male, age 27 years old
The condition of the patient: the hospital diagnoses are frequent micturition, urgent micturition and odynuria.
The implementation scheme is as follows: the fructus Cannabis oil gel candy is taken before meal, 3 times daily for the first 10 days, and 800mg x 4 granules are taken each time; the administration is continued for 20 days, 2 times daily, 800 mg/4 capsules each time.
The result of the scheme is as follows: the frequency, urgency and pain of urination begin to disappear, and the sensation of urethral sting begins to disappear.
The edible and medicinal components of the hemp seed oil, pumpkin seed oil and Cannabidiol (CBD) are matched for use, the hemp seed oil is rich in oleic acid, linoleic acid, alpha-linolenic acid, gamma-linoleic acid (GLA) and other human essential unsaturated fatty acids, and after the gamma-linoleic acid (GLA) enters cell walls, the hemp seed oil can be combined with or inserted into cell membranes to change the fluidity and other physiological properties of the membranes, so that the growth of thalli can be effectively inhibited; the pumpkin seed oil is rich in unsaturated fatty acids such as oleic acid and linoleic acid, contains cucurbitacin, vitamins and mineral substances, supplements elements required by a human body, can eliminate initial swelling of prostate, has a good prevention and treatment effect on urinary system and prostatic hyperplasia, can effectively relieve anxiety, can play a role in metabolism and immunoregulation by regulating and controlling the level of inflammatory factors and controlling the generation of interferon, is healthy and safe, can be taken for a long time, and can effectively improve the symptoms of prostatitis.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (10)
1. A composition for treating prostatitis is characterized in that the effective components of the composition comprise hemp seed oil, pumpkin seed oil and Cannabidiol (CBD), and the weight percentage of the effective components in the composition is 20-100%.
2. The composition as claimed in claim 1, wherein the hemp seed oil is 30-45 wt%, the pumpkin seed oil is 20-50 wt%, and the Cannabidiol (CBD) is 10-40 wt% based on the weight of the active ingredients.
3. The composition of claim 1, wherein the composition is an oral formulation; the preparation is in the form of electuary, distillate, soft capsule, oral liquid, fresh juice, hard capsule, granule, tablet, powder, tea beverage or medicated liquor.
4. The composition of claim 3, wherein the formulation is a vegetable gum type, animal gum type, or precipitated gum type soft capsule.
5. The composition according to claim 4, further comprising an auxiliary material, wherein the auxiliary material comprises the following components in parts by weight: 5-30 parts of glycerol, 5-50 parts of gelatin, 0.2-5 parts of fructose, 0.2-5 parts of sorbitol and 5-50 parts of purified water.
6. A process for the preparation of a composition according to any one of claims 1 to 5, characterized in that it comprises the following steps:
(1) preparing glue solution: putting glycerol and purified water into a device, stirring, adding gelatin, fructose and sorbitol when the temperature of the material liquid is raised to 70-75 ℃, vacuumizing, continuously heating to 80-85 ℃, stirring until the gelatin is completely dissolved, keeping the temperature of the glue solution at 70-75 ℃, vacuumizing again until the glue solution is free of bubbles and the viscosity reaches 20000-;
(2) preparation of gel candy content: mixing oleum Cannabis, semen Cucurbitae oil and Cannabidiol (CBD), stirring, and filtering with 150 mesh sieve;
(3) and (3) granulating: pressing the gel candy content and the glue solution into gel candy by a gel candy machine;
(4) molding: performing the pressed gel candy by a rotating cage, drying until the rubber reaches the preset hardness, and removing unqualified products to obtain the composition for treating prostatitis.
7. The preparation method according to claim 6, wherein the discharging process in the step (1) is carried out by filtering through a single-layer 100-mesh filter bag, and the discharging pressure is not more than 0.06 MPa; keeping the temperature and standing at 70 ℃ for 2-24 h.
8. The method of claim 6, wherein the gel candy of the step (3) has a gum thickness of 0.75 to 0.80 mm; during preparation, the rotation speed of the gel candy machine is 2.0-3.5rpm, the heat preservation temperature of the glue solution is 70 ℃, and the temperature of the spray body is 55 ℃.
9. The method as claimed in claim 6, wherein the predetermined hardness in step (4) is 60 degrees, and the moisture content in the rubber is controlled to be 3-8%.
10. Use of the composition of claims 1-5 for the preparation of health food, specialized medical food and medicament for the treatment of prostatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010032459.5A CN111150756A (en) | 2020-01-13 | 2020-01-13 | Composition for treating prostatitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010032459.5A CN111150756A (en) | 2020-01-13 | 2020-01-13 | Composition for treating prostatitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111150756A true CN111150756A (en) | 2020-05-15 |
Family
ID=70562696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010032459.5A Pending CN111150756A (en) | 2020-01-13 | 2020-01-13 | Composition for treating prostatitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111150756A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109640977A (en) * | 2016-06-02 | 2019-04-16 | 法默技术有限公司 | Cannabidiol composition and application thereof |
-
2020
- 2020-01-13 CN CN202010032459.5A patent/CN111150756A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109640977A (en) * | 2016-06-02 | 2019-04-16 | 法默技术有限公司 | Cannabidiol composition and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 乐养生活: "***炎，你需要4种好食物", 《HTTPS://WWW.SOHU.COM/A/614903_109944》 * |
| 李松: "《健康"心"行动》", 31 March 2012, 广东科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| CN103127045A (en) | Composition containing gamma-aminobutyric acid and lycopene and preparation method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| WO2022227149A1 (en) | Camellia oil and peony seed oil-based gelatin candy and preparation method therefor | |
| CN101955874B (en) | Method for brewing bitter almond liqueur | |
| CN111150756A (en) | Composition for treating prostatitis and preparation method thereof | |
| CN102807411A (en) | Flower-promoting fruit-retention composite fertilizer for Australian nut adult trees | |
| CN110237117A (en) | A kind of soft capsule and preparation method thereof of Menopause anti-aging | |
| CN111067936A (en) | Composition for improving prostatitis and preparation method and application thereof | |
| CN107412626A (en) | A kind of invigorating the spleen to clear away damp pathogen composition and its processing method and the application in clearing damp anti-trioxypurine product | |
| CN104383111A (en) | Kudzu plant fermentation broth and preparation method thereof | |
| KR101227922B1 (en) | Papaya puree and the use of the same | |
| CN109276688B (en) | Traditional Chinese medicine composition for senile dementia | |
| CN106692760A (en) | Golden flower wine formula for preventing diabetes and preparation method thereof | |
| CN113499369A (en) | Composition of peony pistil for treating prostate disease and preparation method thereof | |
| KR101771521B1 (en) | Method of preparing oriental medicine composition for treating thyroid diseases | |
| CN101897747A (en) | Traditional Chinese medicinal health care product used for alleviating eye fatigue and preparation method thereof | |
| CN110367360A (en) | A kind of blood pressure depressing health tea | |
| CN111838653A (en) | Blueberry and grape seed vitamin A soft capsule and preparation method thereof | |
| CN116370549B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN107669852A (en) | A kind of peony seed oil myogenic cream | |
| KR20100129040A (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN106728502A (en) | A kind of hypoglycemic medicinal liquor and its production method | |
| CN112772908A (en) | Preparation method of tea polyphenol-rich medicinal and edible plant enzyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200515 |